Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron

Already approved for atopic dermatitis, the partners have got a PDUFA date of Oct. 20 which could expand the label on their interleukin-4 and -13 inhibitor to include asthma.

Exercise
Looking to expand Dupixent • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc.'s hopes to turn their eczema drug Dupixent (dupilumab) from a big-seller into a mega-blockbuster have been raised by the news that the FDA is reviewing the therapy as a treatment for asthma.

Dupixent, which was approved in March 2017 by the FDA for the treatment of moderate-to-severe atopic dermatitis in adults whose...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category